| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
|
4,209 |
3,335 |
$832K |
| 99282 |
|
3,423 |
2,749 |
$759K |
| 96361 |
|
1,378 |
921 |
$610K |
| 99214 |
|
2,167 |
1,861 |
$425K |
| 99213 |
|
4,446 |
3,760 |
$420K |
| 99284 |
|
2,057 |
1,548 |
$169K |
| 99212 |
|
1,309 |
1,111 |
$84K |
| 87635 |
|
2,096 |
1,757 |
$74K |
| 99285 |
|
1,789 |
1,214 |
$72K |
| 99204 |
|
326 |
279 |
$56K |
| 87502 |
|
751 |
637 |
$53K |
| 96372 |
|
2,257 |
1,540 |
$45K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
563 |
478 |
$44K |
| 99203 |
|
390 |
338 |
$40K |
| 85025 |
|
5,140 |
4,004 |
$26K |
| 96365 |
|
106 |
63 |
$25K |
| 80307 |
|
493 |
353 |
$23K |
| 97112 |
|
1,061 |
355 |
$22K |
| 92507 |
|
502 |
131 |
$21K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
680 |
542 |
$20K |
| 97110 |
|
1,337 |
455 |
$19K |
| 71046 |
|
1,063 |
810 |
$19K |
| 84443 |
|
1,525 |
1,288 |
$19K |
| 80051 |
|
3,773 |
2,810 |
$19K |
| 97140 |
|
808 |
270 |
$16K |
| 70450 |
|
49 |
42 |
$16K |
| 87880 |
|
1,072 |
896 |
$15K |
| 82565 |
|
4,750 |
3,624 |
$15K |
| 96360 |
|
57 |
49 |
$13K |
| 93005 |
|
1,762 |
1,373 |
$12K |
| 80061 |
|
948 |
804 |
$11K |
| 96374 |
|
1,394 |
1,045 |
$10K |
| 84460 |
|
2,734 |
2,220 |
$9K |
| 83036 |
|
959 |
823 |
$8K |
| 82947 |
|
3,050 |
2,545 |
$8K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
458 |
388 |
$8K |
| 36415 |
|
4,414 |
3,299 |
$6K |
| 84450 |
|
1,808 |
1,494 |
$6K |
| 81001 |
|
2,200 |
1,822 |
$6K |
| 74177 |
|
16 |
12 |
$6K |
| 71045 |
|
493 |
382 |
$5K |
| 84075 |
|
1,816 |
1,489 |
$5K |
| 84520 |
|
2,668 |
2,146 |
$5K |
| 82247 |
|
2,025 |
1,602 |
$5K |
| 99202 |
|
83 |
69 |
$5K |
| 85027 |
|
908 |
659 |
$5K |
| 87801 |
|
142 |
114 |
$5K |
| 87081 |
|
419 |
358 |
$4K |
| 83690 |
|
680 |
568 |
$3K |
| 99211 |
|
246 |
186 |
$3K |
| 80048 |
|
534 |
449 |
$2K |
| A0380 |
Bls mileage (per mile) |
159 |
78 |
$2K |
| 81025 |
|
243 |
224 |
$2K |
| 82040 |
|
575 |
472 |
$2K |
| 84484 |
|
447 |
244 |
$2K |
| 85610 |
|
645 |
335 |
$2K |
| 96375 |
|
565 |
422 |
$1K |
| 87086 |
|
372 |
294 |
$1K |
| 97530 |
|
89 |
45 |
$1K |
| 83605 |
|
310 |
234 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
31 |
24 |
$1K |
| 90686 |
|
50 |
47 |
$991.41 |
| 81003 |
|
481 |
419 |
$939.14 |
| 93010 |
|
240 |
190 |
$866.79 |
| 84132 |
|
186 |
148 |
$683.18 |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
97 |
79 |
$489.47 |
| 82310 |
|
168 |
142 |
$426.78 |
| 90656 |
|
19 |
19 |
$396.04 |
| 83735 |
|
113 |
95 |
$347.92 |
| 82306 |
|
14 |
13 |
$305.90 |
| 84145 |
|
41 |
36 |
$304.99 |
| 3008F |
|
29 |
27 |
$260.00 |
| 87077 |
|
69 |
50 |
$248.40 |
| G0378 |
Hospital observation service, per hour |
25 |
12 |
$226.25 |
| 86140 |
|
47 |
37 |
$187.05 |
| 80053 |
|
46 |
40 |
$185.47 |
| 82728 |
|
17 |
12 |
$126.72 |
| 82962 |
|
63 |
37 |
$114.80 |
| 82077 |
|
16 |
13 |
$110.56 |
| J7050 |
Infusion, normal saline solution, 250 cc |
833 |
567 |
$99.68 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,999 |
1,339 |
$80.70 |
| 87186 |
|
18 |
13 |
$71.52 |
| A9270 |
Non-covered item or service |
5,447 |
1,036 |
$56.23 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
109 |
101 |
$30.19 |
| 85018 |
|
14 |
13 |
$24.50 |
| 87040 |
|
27 |
12 |
$21.32 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
52 |
38 |
$10.49 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
494 |
255 |
$9.66 |
| J3490 |
Unclassified drugs |
104 |
82 |
$7.69 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
208 |
93 |
$6.34 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
142 |
108 |
$2.44 |
| A0425 |
Ground mileage, per statute mile |
33 |
26 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
41 |
38 |
$0.00 |